Access 6 Verified Employees Profiles for Keltic Pharma TherapeuticsUnlock Free Contacts Now
About
In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.